BioMarin
  • Our company

    Our company

    • Our science
    • Patient organisations
    • Grants and donations
    • Independent research (For healthcare professionals only)
    • Data request (For healthcare professionals only)
    • Independent medical education (For healthcare professionals only)
    • Career information
    • Investor and media information
  • Our therapy areas

    Our therapy areas

    • Achondroplasia
    • Phenylketonuria (PKU)
    • Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease
    • Mucopolysaccharidosis type IVA (MPS IVA)
    • Mucopolysaccharidosis VI (MPS VI)
  • Our products

    Our products

    • BRINEURA®
    • KUVAN®
    • NAGLAZYME®
    • PALYNZIQ®
    • VIMIZIM®
    • VOXZOGO®
  • For Healthcare Professionals only

    For Healthcare Professionals only

    • VOXZOGO® (Achondroplasia)
    • KUVAN® (PKU)
    • BRINEURA® (CLN2)
    • NAGLAZYME® (MPS VI)
    • VIMIZIM® (MPS IV)
  • Contact us
  • Pharmacy Ordering

Leaving site

Leaving www.biomarin.com/en-au/

Okay Cancel

You’re about to leave the BioMarin Australia website

The information that you are about to be referred to may not comply with the Australian regulatory requirements or be applicable to Australian users. For particulars specifically relevant to the Australian environment contact BioMarin Pharmaceutical Australia Pty Ltd or refer to the appropriate Product Information document.

Leave this website Close

BioMarin

Connect:

  • Careers
  • LinkedIn
  • Facebook
  • YouTube
  • Privacy Policy
  • Terms of Use
  • Supplier Information
  • Supply Chain Statement
  • Cookie Settings

© 2026 BioMarin. All rights reserved.